Percutaneous Repair for Secondary Mitral Regurgitation: No Better Than Medical Therapy Alone

Receipt of the MitraClip device did not improve the 1-year rate of death or heart failure hospitalization.

Patients with severe mitral regurgitation (MR) secondary to reduced left ventricular ejection fraction (LVEF) have poor outcomes. Observational studies have suggested that percutaneous correction of MR improves these patients' symptoms and quality of life, but evidence of benefit for hard endpoints, including survival, is weak for both percutaneous and surgical procedures. In a manufacturer-supported, French multicenter study (NCT01920698), 304 adults (mean age, 70; 75% men) with severe, symptomatic secondary MR (regurgitant volume >30 mL or effective orifice area >20 mm²) and an LVEF of 15% to 40% (mean, 33%) who were not candidates for surgery were randomized to percutaneous MitraClip repair plus medical therapy or medical therapy alone. …

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)